Eris Lifesciences Ltd. (ERIS) Share Price Falls 5.14% Today
- July 30, 2026
- Posted by: Harsh Piplani
- Category: News
Eris Lifesciences Ltd. Share Price experienced a significant decline today, falling by 5.14% to close at Rs 1,353.8. The company’s market capitalisation now stands at Rs 19,281.81 crore. This price fall positions Eris Lifesciences Ltd. The decline in share price is notable given the company’s position within the healthcare sector, which often experiences fluctuations due to various market dynamics.
The decline in Eris Lifesciences Ltd.’s share price today is significant, especially considering the company’s market cap category. As a mid-cap company, the threshold for a notable price fall is set at 5%, and today’s decline has surpassed this mark. The stock opened at Rs 1,391.1 and reached a high of Rs 1,399.2 before falling to a low of Rs 1,353.7. The total trading volume was 66,237 shares, with a turnover of Rs 0.78 crore, indicating active participation in today’s trading session.
Eris Lifesciences Ltd. (ERIS) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,353.8 |
| Previous Close | Rs 1,427.2 |
| Today's Change | Rs -73.4 (-5.14%) |
| Day Open | Rs 1,391.1 |
| Day High | Rs 1,399.2 |
| Day Low | Rs 1,353.7 |
| Current Volume (BSE) | 5,782 |
| BSE Traded Volume | 5,782 |
| NSE Traded Volume | 60,455 |
| Combined NSE + BSE Volume | 66,237 |
| Turnover | Rs 0.78 crore |
| Market Capitalisation | Rs 19,281.81 crore |
| Market Cap Category | Mid Cap |
Eris Lifesciences Ltd. (ERIS) traded at Rs 1,353.8. versus the previous close of Rs 1,427.2, a fall of 5.14%. The stock opened at Rs 1,391.1, reached Rs 1,399.2, touched Rs 1,353.7. Reported volume was 5,782.
Eris Lifesciences Ltd. (ERIS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 19,281.81 crore |
The healthcare sector’s ROE and ROCE averages are 15.15% and 17.62%, respectively. These metrics are crucial for assessing the company’s efficiency in generating returns on equity and capital employed. Eris Lifesciences Ltd.’s performance relative to these benchmarks can provide insights into its operational effectiveness.
While specific earnings per share (EPS), book value, and dividend yield figures for Eris Lifesciences Ltd. are not provided, these metrics are essential for evaluating the company’s financial health and shareholder returns. Investors often look at these indicators to assess the company’s profitability and potential for future growth.
As we move to the ownership analysis, understanding the shareholding pattern can offer additional insights into the company’s market perception and investor confidence.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Benchmark Median P/E | 26.56x |
| Benchmark Average P/E | 87.07x |
| Benchmark P/E Range | 3.47x to 3,385.56x |
| Benchmark Median P/B | 1.91x |
| Benchmark Median ROE | 10.74% |
| Benchmark Median ROCE | 13.24% |
| Company Market Capitalisation | Rs 19,281.81 crore |
| Benchmark Median Market Cap | Rs 138.42 crore |
Eris Lifesciences Ltd. (ERIS) is classified under sector: Healthcare.
Track today’s top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
The healthcare sector, where Eris Lifesciences Ltd. operates, comprises 198 companies, providing a broad benchmark for comparison. The sector’s P/E median is 26.56, with an average of 87.07, indicating a wide range of valuations. The P/B median is 1.91, with an average of 2.57, reflecting the sector’s asset valuation trends.
In terms of profitability, the sector’s ROE and ROCE averages are 15.15% and 17.62%, respectively. These figures highlight the sector’s ability to generate returns on equity and capital employed, which are critical for assessing company performance.
Within this context, Eris Lifesciences Ltd.’s market capitalisation of Rs 19,281.81 crore places it among the larger entities in the sector. The sector’s market cap median is Rs 138.42 crore, with an average of Rs 460.04 crore, showcasing the diversity in company sizes.
Understanding the sector’s dynamics and Eris Lifesciences Ltd.’s position within it is crucial for investors looking to gauge the company’s potential for growth and stability. As we proceed to peer comparison, examining how Eris Lifesciences Ltd. stacks up against its competitors can provide further insights.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,856.59 | 30.28 | 0.44 | -2.89 | -0.26 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,686.76 | 40.11 | 8.17 | 28.21 | 26.35 |
| Hikal Ltd. | HIKAL | 2,676.24 | 0 | 2.27 | 15.22 | 16.15 |
| Panacea Biotec Ltd. | PANACEABIO | 2,540.37 | 0 | 3.11 | 0 | 5.36 |
| Solara Active Pharma Sciences Ltd. | SOLARA | 2,446.19 | 0 | 1.91 | 17.23 | 15.34 |
Eris Lifesciences Ltd. (ERIS) has a market capitalisation of Rs 19,281.81 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Eris Lifesciences Ltd. competes with several notable peers within the healthcare sector. Dishman Carbogen Amcis Ltd. (DCAL) has a P/E of 30.28 and a market cap of Rs 2,856.59 crore, while Kwality Pharmaceuticals Ltd. (KPL) boasts a P/E of 40.11 and a market cap of Rs 2,686.76 crore. Hikal Ltd. (HIKAL) has a market cap of Rs 2,676.24 crore, with a P/B of 2.27.
Panacea Biotec Ltd. (PANACEABIO) and Solara Active Pharma Sciences Ltd. (SOLARA) have market caps of Rs 2,540.37 crore and Rs 2,446.19 crore, respectively. These peers provide a benchmark for evaluating Eris Lifesciences Ltd.’s market positioning and valuation metrics.
Comparing these companies’ P/E, ROE, and ROCE values can offer insights into their relative strengths and weaknesses. Eris Lifesciences Ltd.’s performance in these areas can help investors understand its competitive standing within the sector.
Why Investors Are Watching Eris Lifesciences Ltd.
Investors are closely monitoring Eris Lifesciences Ltd. due to its recent share price decline and its position within the healthcare sector. The company’s market cap and valuation metrics are key areas of interest.
- Significant price fall of 5.14% today.
- Mid-cap category with a market cap of Rs 19,281.81 crore.
- Operates within the dynamic healthcare sector.
- Comparison with peers highlights market positioning.
As the market evolves, investors should keep an eye on Eris Lifesciences Ltd.’s financial performance, sector trends, and any potential changes in its competitive landscape. Monitoring these factors can provide valuable insights into the company’s future trajectory.
About Eris Lifesciences Ltd.
Eris Lifesciences Ltd. is a prominent player in the healthcare sector, focusing on pharmaceuticals and drugs. The company operates within a dynamic industry, offering a range of products and services that cater to various medical needs. Its business segments include the development, manufacturing, and marketing of pharmaceutical products, positioning it as a key contributor to the healthcare landscape.
The company’s revenue mix is diversified, with a focus on innovative solutions that address critical healthcare challenges. Eris Lifesciences Ltd. leverages its expertise in research and development to drive growth and maintain its competitive edge in the industry.
As a mid-cap company, Eris Lifesciences Ltd. plays a significant role in the healthcare sector, contributing to its overall growth and development. The company’s commitment to quality and innovation positions it as a trusted partner in the medical community.
Track Eris Lifesciences Ltd. Share Price on Univest
Use Eris Lifesciences Ltd. (ERIS) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.
Investors can track Eris Lifesciences Ltd. Share Price and gain insights into its performance on Univest. The platform offers live updates on share price, technical indicators, fundamental ratios, and shareholding patterns. Additionally, users can access information on 52-week levels and market insights, providing a comprehensive view of the company’s market position.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What caused Eris Lifesciences Ltd. Share Price to fall today?
Ans. Eris Lifesciences Ltd. Share Price fell by 5.14% today, closing at Rs 1,353.8. The decline was significant enough to surpass the mid-cap category threshold of 5%. The stock moved -5.14% during the session.
What is the significance of Eris Lifesciences Ltd.'s sector positioning?
Ans. Eris Lifesciences Ltd. operates in the healthcare sector, which is known for its volatility. Its market cap of Rs 19,281.81 crore highlights its significant role in the industry. The stock belongs to the Healthcare sector.
How does Eris Lifesciences Ltd. compare to its peers?
Ans. Eris Lifesciences Ltd. competes with peers like Dishman Carbogen Amcis Ltd. and Kwality Pharmaceuticals Ltd., with varying P/E and market cap metrics. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Hikal Ltd.
What is the sector benchmark for ROE and ROCE?
Ans. The healthcare sector's ROE average is 15.15%, and the ROCE average is 17.62%, providing a benchmark for company performance. The relevant peer median ROE is 10.74%. The relevant peer median ROCE is 13.24%.
